TrialThe Journal of clinical endocrinology and metabolism2021

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.

Melissa K Thomas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.